Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs

Journal of Nutrition, Health and Aging

Volumn 10, Issue 2, 2006, Pages 123-128

  Scheltens, P ^a   Barkhof, F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; BRAIN ATROPHY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE COURSE; DISEASE MARKER; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TEMPORAL LOBE; WHITE MATTER;

EID: 33646040987     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143-1153.
2. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS- ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
3. American Psychiatric Association (1997) Diagnostic and statistical manual of mental disorders, Fourth Edition, Washington, DC: American Psychiatric Association.
4. Chui H, Young Lee, A. Clinical criteria for various dementia subtypes: Alzheimer disease (AD), vascular dementia (VaD) Dementia with Lewy bodies (DLB), and Frontotemporal dementia (FTD). In: Qizilbash N, Schneider L, Chui H. Brodaty H, Kaye J, Erkinjuntti T, eds. Evidence based Dementia. Oxford: Blackwell Science, Ltd., 2002:
5. Petrovitch H, White LR, Ross GW, et al. Accuracy of clinical criteria for AD in the Honolulu-Asia aging study, a population based study. Neurology 2001;57:226-34.
6. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DMA, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 1999;66:184-88.
7. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiology of Aging 1997;18(4):351-7.
8. Linn RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Belanger AJ et al. The 'preclinical phase' of probable Alzheimer's disease. A 13- year prospective study of the Framingham cohort. Arch Neurol 1995;52:485-90.
9. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001;58(3):411-416.
10. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC et al. Patterns of brain activation in people at risk for Alzheimer's disease. N.Engl.J.Med. 2000;343(7):450-6.
11. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001;58(3):397-405.
12. Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, et al. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 1999;246(6):477-485.
13. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry 2002;72(4):491-497.
14. Convit A, De Leon MJ, Tarshish C, De Santi S, Tsui W, Rusinek H, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging 1997;18(2):131-138.
15. Korf ESC WL-O, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in subjects with mild cognitive impairment. Neurology 2004;63:94-101.
16. Convit A, de Asis J, de Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging 2000;21(1):19-26.
17. Jack CR, Jr., Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52(7):1397-1403.
18. Jack CR, Jr., Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55(4):484-489.
19. Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 2001;22(5):747-754.
20. Laakso MP, Soininen H, Partanen K, Lehtovirta M, Hallikainen M, Hanninen T, et al. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 1998;19(1):23-31.
21. Laakso MP, Frisoni GB, Kononen M, Mikkonen M, Beltramello A, Geroldi C, et al. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease: a morphometric MRI study. Biol Psychiatry 2000;47(12):1056-1063.
22. Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ, Soininen H. Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study. Biol Psychiatry 2000;47(6):557-561.
23. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999;52(6):1153-1158.
24. Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O'Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000;15(10):911-916.
25. Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000;54(6):1304-1309.
26. Barber R, Panikkar A, McKeith IG. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 2001;16Suppl 1:S12-18.
27. Barber R, McKeith IG, Ballard C, Gholkar A, O'Brien JT. A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord 2001;12(3):198-205.
28. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250-60.
29. Scheltens P, Erkinjunti T, Leys D, Wahlund LO, Inzitari D, del Ser T. et al. White matter changes on CT and MRI: an overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol 1998;39(2):80-89.
30. Van Straaten ECW, Scheltens P, Knol D, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia. An interobserver study. Stroke 2003;34:1907-1912.
31. Walters RJ, Fox NC, Crum WR, Taube D, Thomas DJ. Haemodialysis and cerebral oedema. Nephron 2001;87(2):143-147.
32. Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004 Feb 24;62(4):591-600
33. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000 Mar;57(3):339-44
34. Smith SM, De Stefano N, Jenkinson M, Matthews P. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001; 25: 466-75.
35. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:1489-96.
36. Gunter JL, Shiung MM, Manduca A, Jack CR Jr. Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imaging. 2003;18:16-24
37. Shear PK, Sullivan EV, Mathalon DH, et al. Longitudinal volumetric computed tomographic analysis of regional brain changes in normal aging and Alzheimer's disease. Arch Neurol. 1995;52:392-402.
38. Thompson PM, Mega MS, Wood RP, et al. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cerebral Cortex 2001; 11: 1-16.
39. Csernansky JG, Wang L, Joshi S, et al. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Neurology 2000; 55: 1636-43.
40. Jack CR, Jr., Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998;51(4):993-999.
41. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurology 2002;1:13-21.
42. Wahlund LO, Julin P, Lindqvist J, Scheltens P. Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Res 1999;90(3):193-199.
43. Haller JW, Banerjee A, Christensen GE, Gado M, Joshi S, Miller MI, et al. Three-dimensional hippocampal MR morphometry with high-dimensional transformation of a neuroanatomic atlas. Radiology 1997;202(2):504-510.
44. Crum WR, Scahill RI, Fox NC. Automated hippocampal segmentation by regional fluid registration of serial MRI: validation and application in Alzheimer's disease. Neuroimage 2001;13(5):847-855.
45. Du AT, Schuff N, Zhu XP, Jagust WJ, Miller BL, Reed BR, et al. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology 2003;60(3):481-6.
46. Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;71(4):441-7.
47. Chan D, Fox NC, Scahill RI, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol. 2001 Apr;49(4):433-42.
48. Birkenhager WH, Forette F, Staessen JA. Dementia and antihypertensive treatment. Curr Opin Nephrol Hypertens. 2004 Mar;13(2):225-30.
49. Scheltens Ph, Kittner B. Preliminary Results From An MRI/CT-Based Database for Vascular Dementia and Alzheimer's Disease. Ann NY Acad Sci. 2000;903:542-7.
50. Schmidt, R., Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet, 2003. 361: 2046-2048.
51. Wahlund, L., Almkvist O, Basin H, Julin P. MRI in successful ageing, a 5-year follow-up study from eighth to ninth decade of life. Magn Res Imag, 1996. 14: 601-608.
52. Veldink, J., Scheltens P, Jonker C, Launer LJ. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology, 1998. 51:. 319-320.
53. Schmidt, R., Fazekas F, Kapeller P, Schmidt H, Hartung H-P. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology, 1999. 53:132-139.
54. Whitman, G., Tang T, Lin MA, Baloh RW. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. Neurology, 2001. 57: 990-994.
55. DeCarli C, Swan GE, Park M, Reed T, Wolf PA, Carmelli D. Longitudinal changes in brain and white matter hyperintensity volumes among elderly male twins from the NHLBI twin study. Neurology 2002; 58(suppl 3):A399.
56. Prins ND, van Straaten EC, van Dijk EJ, Simoni M, van Schijndel RA, Vrooman HA, Koudstaal PJ, Scheltens P, Breteler MM, Barkhof F. Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology 2004;62:1533-9.
57. Bradley KM, Bydder GM, Budge MM, Hajnal JV, White SJ, Ripley BD, Smith AD. Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Br J Radiol. 2002 Jun;75(894):506-13
58. Schmidt R, Scheltens P, Erkinjuntti T, Pantoni L, Markus HS, Wallin A, Barkhof F, Fazekas F, for the European Task Force on Age-Related White Matter Changes. White matter lesion progression: A surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004;63:139-144.